Sermorelin

Product Overview: Sermorelin

Sermorelin (Sermorelin Acetate / GRF 1-29) is a synthetic 29-amino acid peptide representing the functional N-terminal fragment of naturally occurring human Growth Hormone-Releasing Hormone (GHRH 1-44). Engineered to preserve full receptor-binding capability, Sermorelin acts as a selective GHRH receptor agonist in the anterior pituitary gland. By stimulating the natural synthesis and secretion of endogenous Growth Hormone (GH), Sermorelin serves as an essential research model for evaluating endocrine axis regulation, pituitary reserve function, and age-related somatopause dynamics.

Primary Research Applications & Reasons for Study

• Pituitary GHRH Receptor Stimulation: Binding directly to somatotroph receptors in the anterior pituitary to induce adenylate cyclase activity and drive intracellular cAMP-dependent GH release.
• Pituitary Axis Reserve Assessment: Evaluating pituitary functional responsiveness and endogenous somatotroph reserve capacity in aging or deficient animal models.
• GHRP/Secretagogue Synergy: Investigating amplified, dual-signaling GH pulses when co-administered alongside ghrelin receptor agonists (e.g., Ipamorelin or GHRP-2).
• Metabolic & Anabolic Regulation: Assessing downstream IGF-1 elevation, protein accretion rates, and lipolytic fatty acid mobilization under physiological feedback control.

Expected Research Results & Timeline Metrics

• Phase 1 / Minutes 15–45
  Acute Endogenous GH Pulse: Direct activation of somatotroph GHRH receptors triggers a rapid spike in circulating serum Growth Hormone levels, peaking within ~30 minutes.
• Phase 2 / Weeks 1–3
  Hepatic IGF-1 Upregulation: Sustained elevation of baseline serum IGF-1 levels, increased cellular nitrogen retention, and early shifts toward enhanced lipid oxidation.
• Phase 3 / Weeks 4–8+
  Compositional & Functional Adaptation: Statistically significant increases in lean tissue mass, improved bone mineral accretion markers, and reduced total fat mass without desensitizing the pituitary axis.

Key Research Benefits

• Short Functional Sequence: Contains the shortest functional peptide chain (29 amino acids) capable of fully retaining native GHRH bioactivity and receptor affinity.
• Preserves Physiological Feedback: Stimulates GH secretion while remaining subject to natural somatostatin (GH-inhibiting hormone) feedback, preventing non-physiological hyper-secretion.
• Synergistic Multi-Secretagogue Potential: Works via an independent signaling pathway from GHRPs/ghrelin agonists, enabling powerful co-stimulation protocols.
• Gold-Standard Neuroendocrine Tool: Established benchmark compound for investigating somatotroph health, hypothalamic aging, and secretagogue response curves.